GBA Presents: RADIO SAVANT-!

vanzandt said:
I think today... we'll make PATH the Gummy of the Day.
PATH $12.55 pre-market as I type.
Volume 460 shares. ;)


* ON NOV 10, BOARD APPROVED FURTHER RESTRUCTURING ACTIONS OF 6% OF THE CO'S GLOBAL WORKFORCE

* UIPATH(PATH)- ACTIONS EXPECTED TO INCLUDE AN ADDITIONAL REDUCTION ACROSS FUNCTIONS OF ABOUT 6% OF CO'S GLOBAL WORKFORCE OF ABOUT 4,025 AS OF OCT 31, 2022

* MOST OF THESE WORKFORCE REDUCTIONS EXPECTED TO OCCUR BY THE END OF FISCAL YEAR 2023

* NOW EXPECTS TOTAL RESTRUCTURING EXPENSES OF APPROXIMATELY $30 MILLION

* CONTINUE TO ANTICIPATE MAJORITY OF THE TOTAL CHARGES RELATED TO RESTRUCTURING WILL BE RECOGNIZED, PAID BY THE END OF FISCAL YEAR 2023

* SEES Q3 2023 REVENUE OF ABOUT $260 MILLION

* SEES Q3 2023 ARR OF ABOUT $1.108 BILLION AS OF OCT 31, 2022

* Q3 REVENUE VIEW $245.3 MILLION
More...
PATH is $13.03 on the ask now... 14K shares traded.
The tide will carry this one up nicely today.
 
Oh god... Stoney's in the house now.
Here comes the morning blitz of cut and pastes from Yahoo and Seeking Alpha.
Time to hand the microphone to the drummer, let him have a little fun. :cool:
 
-> Time To Roll The Dice (again) -?

Dice Therapeutics initiated with a Buy at Guggenheim 06:33 DICE Guggenheim analyst Seamus Fernandez initiated coverage of Dice Therapeutics with a Buy rating and $65 price target. Dice's lead compound, DC-806, recently achieved early clinical proof of concept, which Fernandez calls "a potential breakthrough in industry-wide efforts targeting IL-17." The analyst, who sees "multibillion-dollar potential" for DC-806, thinks a three-times or greater return could perhaps be "catalyzed by a major global partnership or M&A event" should Phase 1 results for DC-853 imply once-daily best-in-class potential in its 2023 readout and Phase 2b results show efficacysimilar to Cosentyx, Fernandez tells investors.
 
X-Ray reveals lack of earnings.

Dentsply Sirona reports Q3 adjusted EPS 41c, consensus 57c 15:25 XRAY Reports Q3 revenue $947M, consensus $1.03B. "Our third quarter results reflect continued macroeconomic headwinds, including foreign currency impacts, global supply chain challenges, and regional softness in the U.S. and China. Despite the challenges this quarter, we were encouraged by double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment," said Simon Campion, Chief Executive Officer. "We are not satisfied with third quarter results, however this quarter marks an important turning point as we enter our company's next chapter. We have initiated a comprehensive review of our entire business in order to improve our execution, build a winning portfolio, and return the Company to growth. Dentsply Sirona has great products and solutions, a healthy innovation pipeline, and we are committed to charting a path forward which delivers better and more consistent results for our shareholders."
 
vanzandt said:
Stoney!!!!
The Gingko
DNA
It's way down on the earnings.... buy it.
$2.53
More...





Ginkgo Bioworks down 7% as it sees fewer new cell programs, lower Foundry revenue range :caution:

Cathie boots another one... I like the old pictures of her a lot better, feel the same way about myself.
 
stonedinvestor said:
X-Ray reveals lack of earnings.

Dentsply Sirona reports Q3 adjusted EPS 41c, consensus 57c 15:25 XRAY Reports Q3 revenue $947M, consensus $1.03B. "Our third quarter results reflect continued macroeconomic headwinds, including foreign currency impacts, global supply chain challenges, and regional softness in the U.S. and China. Despite the challenges this quarter, we were encouraged by double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment," said Simon Campion, Chief Executive Officer. "We are not satisfied with third quarter results, however this quarter marks an important turning point as we enter our company's next chapter. We have initiated a comprehensive review of our entire business in order to improve our execution, build a winning portfolio, and return the Company to growth. Dentsply Sirona has great products and solutions, a healthy innovation pipeline, and we are committed to charting a path forward which delivers better and more consistent results for our shareholders."
More...
That's from yesterday.
 
You must log in or register to reply here.
Back
Top